Navigation Links
Reprogram stem cells with heart tissue, which might improve treatments for heart disease
Date:5/19/2010

This release is available in Spanish.

Spanish researchers have employed for the first time adult cells extracted from a human heart to turn stem cells from adipose tissue into cardiac myocytes. In other words, they achieved to "reprogram" adult stem cells, which might improve treatments for heart disease therapeutical.

At present, the use of stem cells in treatments for heart disease is one of the most common practices. However, working with stem cells without targeting heart tissue negatively affects the efficacy of treatments. Therefore, inducing cell differentiation into cardiac muscle (cardiomyocytes) may be one of the best options in the treatment of these pathologies.

For the purpose of this study, researchers isolated adult human stem cells from lipoaspiration. Subsequently, these cells were temporarily permeabilized and exposed to a human-auricle cell extract. Then, these cells were recovered in culture.

Morphological Changes

After 21 days in culture, the cells differentiated towards a cardiac myocyte phenotype, which was demonstrated by expression of morphological changes (appearance of binuclear cells with striated fibers and ramifications), detection of cardiospecific markers through inmunofluorescence, and the presence of cardiac muscle-related genes that were analysed through RT-PCR; and finally, by expression of reverse transcription. Thus, mesenchimal stem cells acquired a cardiac phenotype.

This study was conducted by Macarena Pern, Juan A. Marchal, Elena Lpez, Manuel Jimnez-Navarro, Houria Boulaiz, Fernando Rodrguez-Serrano, Esmeralda Carrillo, Gema Snchez-Espn, Eduardo de Teresa, David Tosh y Antonia Arnega, researchers from the University of Jaen (Spain), the University of Granada, the Hospital Clnico Universitario of Malaga and the University of B
'/>"/>

Contact: Antonia Aranega Jimenez
aranega@ugr.es
34-958-243-534
University of Granada
Source:Eurekalert

Page: 1 2

Related biology news :

1. March of Dimes awards $250,000 prize to scientist who discovered how to reprogram human cells
2. Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming
3. Tumor suppressor pulls double shift as reprogramming watchdog
4. Reprogramming human cells without inserting genes
5. Study reveals a reprogrammed role for the androgen receptor
6. Study finds blood cells can be reprogrammed to act as embryonic stem cells
7. Researchers piggyback to safer reprogrammed stem cells
8. Reprogrammable cell type depends on a single gene to keep its identity
9. Salk researchers successfully reprogram keratinocytes attached to a single hair
10. Yamanaka eliminates viral vector in stem cell reprogramming
11. Salk researchers reprogram adult stem cells in their natural environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... a complex cocktail of poisonous peptides that immobilize animal ... this cocktail damage only insects, which is why a ... a safe and ecologically sound pesticide. Prof. Michael ... has isolated the genetic sequences for important neurotoxins in ...
... the lichen Phylloblastia fortuita , new to the Iberian ... Phylloblastia dispersa , is also a new entry for ... outside the tropics. Foliicolous lichens, symbiosis between fungi ... and their presence in environments such as the Iberian Peninsula, ...
... COLUMBUS, Ohio Blocking the function of an enzyme in ... prevent nerve cells from dying after a stroke, new research ... found that the tocotrienol form of vitamin E, an alternative ... fatty acids that eventually kill neurons. The Ohio State ...
Cached Biology News:A deadly scorpion provides a safe pesticide 2A new species of lichen discovered in the Iberian Peninsula 2Study reveals how one form of natural vitamin E protects brain after stroke 2Study reveals how one form of natural vitamin E protects brain after stroke 3
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® announced the ... venture will bring the world’s most efficient gas dissolution technology to all of ... to both the industrial and municipal markets. With offices located in Sarasota, Sebring ...
(Date:7/27/2015)... July 27, 2015 Junto Health, a company ... information and develop new technology solutions, today announced the ... (SPG), a leader in health care policy consulting. Working ... in a collaborative innovation process while, at the same ... in public policy, health care finance and the delivery ...
(Date:7/26/2015)... (PRWEB) , ... July 26, 2015 , ... ... of its VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA ... Each VALIDATE® ANEMIA kit is prepared using the CLSI recommended “equal delta” method ...
(Date:7/24/2015)... ... ... VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency ... opportunities. , “We are very excited to be able to partner with VetStem Biopharma ... therapy is an established treatment for arthritic conditions in our pets and is also ...
Breaking Biology Technology:BlueInGreen Brings Water Treatment Technology to Florida 2Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3
... , RICHMOND, Va., July 31 Insmed Inc. ... that it will host a conference call on Thursday, August ... for the second quarter 2009. Insmed intends to issue ... on August 13(th). , , To participate ...
... TOKYO, July 31 R-Tech Ueno, Ltd. announced on July ... board of directors held on the day and determined the R&D ... to actively strengthen R&D in the ophthalmologic & dermatological fields that ... with external entities. , , 1. Development code ...
... , , , ... ANDS ) today announced finalization of the protocol for the ... ribavirin in hepatitis C patients. Allowance of the protocol has been ... dosing is expected to commence within the next several weeks. , ...
Cached Biology Technology:Insmed to Host Second Quarter 2009 Conference Call 2R-Tech Ueno Notifies R&D Items 2R-Tech Ueno Notifies R&D Items 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 2Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 3Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 4Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients 5
... Mouse monoclonal antibody raised ... Immunogen: ... 206 a.a) partial recombinant protein ... Accession Number: NM_005802 ...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Agarose II (Low Melt)...
...
Biology Products: